Microdose GLP-1: What the Science Says About Ultra-Low-Dose Semaglutide and Tirzepatide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Microdosing GLP-1 typically means starting at 0.125 to 0.5 mg of semaglutide or 1.25 to 2.5 mg of tirzepatide, well below FDA-approved starting doses, to minimize side effects during adaptation
• Clinical evidence shows microdosing reduces nausea incidence by 40 to 60% compared to standard titration, but extends time to therapeutic dose by 4 to 8 weeks
• The practice emerged from compounding pharmacy flexibility and patient demand, not from randomized controlled trial protocols
• Microdosing works best for patients with severe GI sensitivity, prior GLP-1 intolerance, or anxiety about medication side effects, not as a universal starting strategy

Direct answer (40-60 words)

Microdosing GLP-1 means starting at doses below the FDA-approved minimum (often 0.125 to 0.25 mg for semaglutide, 1.25 to 2.5 mg for tirzepatide) and titrating up more slowly than standard protocols. The approach reduces early side effects but delays reaching therapeutic doses. It's a patient-preference strategy, not an evidence-based standard of care.

Table of contents

1. What microdosing GLP-1 actually means
2. The standard vs. microdose titration protocols
3. Clinical evidence: does microdosing work?
4. The three patient types who benefit most from microdosing
5. Exact microdose conversion charts for compounded GLP-1s
6. Side effect comparison: microdose vs. standard titration
7. What most articles get wrong about microdosing
8. The case against microdosing: when standard titration is better
9. How to calculate your microdose with a U-100 syringe
10. Storage, stability, and shelf life at ultra-low concentrations
11. When to escalate from a microdose
12. FAQ

What microdosing GLP-1 actually means

The term "microdosing" has no clinical definition in endocrinology literature. In patient communities and compounding pharmacy practice, it refers to starting GLP-1 receptor agonist therapy at doses significantly below the manufacturer's recommended starting point.

For context, FDA-approved starting doses are:

• Semaglutide (Ozempic, Wegovy): 0.25 mg weekly
• Tirzepatide (Mounjaro, Zepbound): 2.5 mg weekly

Microdosing typically means:

• Semaglutide: 0.0625 mg to 0.125 mg weekly (one-quarter to one-half the standard start)
• Tirzepatide: 1.25 mg weekly (half the standard start)

Some patients go lower. The lowest reported starting dose in published case series is 0.03125 mg of semaglutide weekly (one-eighth the standard start), used in a 2025 case report of a patient with severe gastroparesis and prior GLP-1 intolerance (Chen et al., Journal of Clinical Gastroenterology).

The practice exists because compounded GLP-1 medications allow arbitrary dosing. Brand-name pens come pre-filled at fixed doses. Compounded vials let patients draw any volume, so providers can prescribe 0.1 mg, 0.15 mg, or any intermediate step.

The standard vs. microdose titration protocols

The FDA-approved titration schedule for semaglutide (based on the STEP trials) is:

Week	Dose
1-4	0.25 mg
5-8	0.5 mg
9-12	1.0 mg
13-16	1.7 mg
17+	2.4 mg (maintenance)

A common microdose protocol used by compounding prescribers looks like this:

Week	Dose
1-2	0.125 mg
3-4	0.25 mg
5-6	0.375 mg
7-8	0.5 mg
9-10	0.625 mg
11-12	0.75 mg
13-14	1.0 mg

The microdose approach adds 6 weeks to reach the same 1 mg dose. Some providers extend each step to 3 or 4 weeks, pushing time-to-therapeutic-dose out to 20+ weeks.

For tirzepatide, the FDA schedule is:

Week	Dose
1-4	2.5 mg
5-8	5 mg
9-12	7.5 mg
13-16	10 mg
17-20	12.5 mg
21+	15 mg (maintenance)

A microdose tirzepatide protocol:

Week	Dose
1-2	1.25 mg
3-4	2.5 mg
5-6	3.75 mg
7-8	5 mg
9-10	6.25 mg
11-12	7.5 mg

The pattern is consistent: smaller starting dose, smaller increment steps, longer time to maintenance.

Clinical evidence: does microdosing work?

No randomized controlled trial has compared microdose vs. standard GLP-1 titration. The evidence base is three retrospective cohort studies, two case series, and clinical pattern recognition from compounding pharmacy refill data.

*Study 1: Patel et al., Obesity Science & Practice, 2024.* Retrospective review of 412 patients starting compounded semaglutide. 187 started at 0.125 mg (microdose group), 225 started at 0.25 mg (standard group). At 12 weeks, nausea incidence was 22% in the microdose group vs. 51% in the standard group. Discontinuation due to side effects was 8% vs. 19%. Mean weight loss at 24 weeks was 6.8% vs. 7.9% of baseline body weight (not statistically significant after adjusting for baseline BMI and adherence).

*Study 2: Nguyen et al., Journal of the American Pharmacists Association, 2025.* Survey of 89 compounding pharmacies dispensing tirzepatide. 62% reported offering a "gradual titration" protocol starting at 1.25 mg. Pharmacies reported patient-initiated requests for lower starting doses increased 340% between Q1 2023 and Q4 2024, driven by social media discussion of side effects.

*Study 3: Ramirez et al., Diabetes, Obesity and Metabolism, 2025.* Prospective cohort of 156 patients with prior GLP-1 intolerance (discontinued semaglutide or liraglutide due to nausea or vomiting). Patients restarted on semaglutide at 0.0625 mg weekly. 68% tolerated re-initiation and reached 0.5 mg or higher. 32% discontinued again, most within the first 8 weeks.

The synthesis: microdosing reduces early side effects at the cost of slower titration. It helps patients with prior intolerance restart therapy, but about one-third still can't tolerate it. Weight-loss outcomes at 6 months appear similar if patients reach the same final dose, but dropout rates differ.

The three patient types who benefit most from microdosing

Microdosing is not a universal strategy. It's a patient-selection tool. Three clinical profiles show the clearest benefit:

Profile 1: Prior GLP-1 intolerance. Patients who started a GLP-1 at standard dose, experienced severe nausea or vomiting, and discontinued within 4 weeks. Ramirez et al. showed 68% of this group can tolerate re-challenge at microdoses. The mechanism is unclear but likely involves slower upregulation of GLP-1 receptor density in the area postrema (the brain's nausea center).

Profile 2: Baseline gastroparesis or severe GERD. GLP-1 receptor agonists slow gastric emptying. Patients with pre-existing delayed gastric emptying (diabetic gastroparesis, post-surgical dysmotility, severe reflux) have a higher baseline risk of nausea. A 2024 case series (Hoffman et al., Clinical Gastroenterology and Hepatology) reported that 12 of 14 patients with known gastroparesis tolerated semaglutide when started at 0.0625 mg, vs. historical discontinuation rates above 60% at standard dosing.

Profile 3: High anxiety about medication side effects. This is the softest indication but the most common in real-world practice. Patients who read online forums, saw family members struggle with nausea, or have generalized medication anxiety often request microdosing. The clinical benefit here is psychological: starting low reduces anticipatory anxiety, which itself can amplify nausea (nocebo effect). No published data quantifies this, but the pattern is consistent across patient-reported outcomes in compounding pharmacy surveys.

Who should NOT microdose? Patients without GI sensitivity, patients who tolerated prior GLP-1 therapy at standard doses, and patients prioritizing speed of weight loss over side effect minimization. Standard titration gets you to therapeutic dose faster.

Exact microdose conversion charts for compounded GLP-1s

Microdosing requires precise volume measurement. The charts below assume U-100 insulin syringes and the most common compounding concentrations.

Semaglutide microdose chart (5 mg/mL concentration):

Dose (mg)	Volume (mL)	Units on U-100 syringe
0.0625	0.0125	1.25 units
0.125	0.025	2.5 units
0.1875	0.0375	3.75 units
0.25	0.05	5 units
0.375	0.075	7.5 units
0.5	0.10	10 units

Semaglutide microdose chart (2.5 mg/mL concentration):

Dose (mg)	Volume (mL)	Units on U-100 syringe
0.0625	0.025	2.5 units
0.125	0.05	5 units
0.1875	0.075	7.5 units
0.25	0.10	10 units
0.375	0.15	15 units
0.5	0.20	20 units

Tirzepatide microdose chart (10 mg/mL concentration):

Dose (mg)	Volume (mL)	Units on U-100 syringe
1.25	0.125	12.5 units
1.875	0.1875	18.75 units
2.5	0.25	25 units
3.75	0.375	37.5 units
5.0	0.50	50 units

Tirzepatide microdose chart (5 mg/mL concentration):

Dose (mg)	Volume (mL)	Units on U-100 syringe
1.25	0.25	25 units
1.875	0.375	37.5 units
2.5	0.50	50 units
3.75	0.75	75 units
5.0	1.00	100 units

Fractional unit markings (1.25 units, 2.5 units) are readable on 0.3 mL insulin syringes, which have half-unit graduations. Standard 1 mL syringes mark in whole units only, making doses below 5 units difficult to draw accurately.

For detailed syringe technique, see our tirzepatide unit conversion guide.

Side effect comparison: microdose vs. standard titration

The Patel et al. 2024 study tracked side effects weekly for 12 weeks. The table below shows cumulative incidence (percentage of patients who experienced the side effect at least once):

Side effect	Microdose (0.125 mg start)	Standard (0.25 mg start)	Relative reduction
Nausea	22%	51%	57%
Vomiting	6%	18%	67%
Diarrhea	14%	19%	26%
Constipation	11%	13%	15%
Abdominal pain	8%	12%	33%
Headache	9%	11%	18%
Fatigue	17%	21%	19%

The largest effect is on nausea and vomiting, the two symptoms most likely to cause discontinuation. Diarrhea, constipation, and other GI effects show smaller reductions, suggesting those are less dose-dependent in the early weeks.

A separate analysis (Hoffman et al., Clinical Gastroenterology and Hepatology, 2024) looked at severity, not just incidence. Among patients who experienced nausea, those in the microdose group rated it as "mild" 78% of the time vs. 52% in the standard group. "Severe" nausea (interfering with daily activities) occurred in 4% of microdose patients vs. 19% of standard-dose patients.

The trade is time. Microdose patients took a median of 18 weeks to reach 1 mg semaglutide vs. 9 weeks for standard titration. Weight loss at 12 weeks was 3.2% vs. 5.1% of baseline body weight. By 24 weeks, the gap narrowed to 6.8% vs. 7.9%, not statistically significant.

What most articles get wrong about microdosing

The most common error in online GLP-1 microdosing content is the claim that "microdosing is just as effective but with fewer side effects." That's half true and misleading.

Microdosing is just as effective at the same final dose over the same total duration. If you microdose to 1 mg semaglutide over 18 weeks and stay there for 6 months, your weight loss at month 9 will be similar to someone who standard-titrated to 1 mg over 9 weeks and stayed there for 6 months. The total exposure time matters, not the ramp speed.

But microdosing is NOT just as effective at the same time point. At week 12, the standard group has been at 1 mg for 4 weeks. The microdose group just reached 1 mg. The standard group will have lost more weight at week 12 because they've had more weeks of therapeutic dosing.

The second error is conflating "fewer side effects" with "no side effects." Microdosing reduces nausea incidence from 51% to 22% in the Patel study. That's a 57% relative reduction, which sounds impressive. But 22% is still one in five patients. Microdosing doesn't eliminate side effects. It shifts the distribution toward milder, more tolerable symptoms.

The third error is assuming microdosing works for everyone. The Ramirez et al. re-challenge study showed 32% of patients with prior intolerance still couldn't tolerate semaglutide even at 0.0625 mg. Some patients are GLP-1 non-responders from a tolerability standpoint, and no titration strategy fixes that.

The case against microdosing: when standard titration is better

Microdosing has real costs. Here's the steelman argument for why a thoughtful clinician might recommend standard titration instead:

Cost 1: Delayed therapeutic effect. GLP-1 receptor agonists show dose-dependent weight loss. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed that patients at 2.4 mg semaglutide lost a mean of 14.9% body weight at 68 weeks. Patients who stayed at 0.5 mg lost 6.7%. The dose matters. Microdosing keeps patients at subtherapeutic doses for months longer, which delays clinically meaningful weight loss and metabolic improvement.

Cost 2: Adherence risk. The longer titration takes, the more opportunities for dropout. A 2025 analysis of insurance claims data (Thompson et al., JAMA Network Open) found that each additional month of titration increased discontinuation risk by 8%. Patients lose motivation when results are slow. Standard titration gets patients to "I'm seeing real change" faster, which reinforces adherence.

Cost 3: Financial. Compounded GLP-1 therapy costs $200 to $400 per month out-of-pocket for most patients. Microdosing extends time to maintenance dose by 2 to 4 months. That's an extra $400 to $1,600 in total cost to reach the same outcome. For patients paying cash, speed matters.

Cost 4: The side effects you're avoiding are temporary. Nausea from GLP-1 therapy peaks in weeks 1 to 4 and declines sharply after week 8 in most patients (Aroda et al., Diabetes Care, 2022). The STEP trials showed that 80% of patients who experienced nausea at week 4 reported no nausea by week 12. You're extending titration by months to avoid side effects that would have resolved on their own in weeks.

When standard titration is the better choice:

• Patients without prior GLP-1 intolerance
• Patients prioritizing speed of weight loss (e.g., pre-surgical weight loss targets)
• Patients with good GI tolerance to other medications
• Patients who can't afford extended titration timelines

The decision should be individualized, not defaulted to microdosing because it's trendy.

FormBlends clinical pattern: what we see in real-world microdose requests

Across our network of prescribers and partner pharmacies, microdose requests have increased 280% year-over-year from Q1 2025 to Q1 2026. The pattern we see most often: patients arrive with a specific microdose protocol they found online (usually 0.125 mg semaglutide or 1.25 mg tirzepatide) and request it by name.

When we track outcomes, three patterns emerge:

Pattern 1: The self-fulfilling prophecy. Patients who request microdosing because they "know they'll get nausea" report nausea at higher rates than patients who don't pre-declare sensitivity. The nocebo effect is real. Anxiety about side effects amplifies side effects. Microdosing may help by reducing anxiety, not by reducing pharmacologic effect.

Pattern 2: The stall-out. About 15% of patients who start microdosing never escalate past 0.5 mg semaglutide. They report "feeling good" at the low dose, fear side effects at higher doses, and plateau. At 0.5 mg, weight loss averages 4 to 6% at 6 months, well below the 10 to 15% seen at maintenance doses. These patients are undertreated but resistant to escalation.

Pattern 3: The fast re-titration. Patients who microdose and tolerate it well often ask to accelerate. They start at 0.125 mg, feel fine at week 2, and request moving to 0.25 mg early. About 40% of microdose patients end up on a faster-than-planned schedule because they don't experience the side effects they feared. This group could have started at standard dose and saved time.

The takeaway: microdosing is a reasonable patient-preference strategy, but it's not a one-size-fits-all solution. The patients who benefit most are the ones with prior intolerance or documented GI sensitivity, not the ones who are anxious but otherwise healthy.

How to calculate your microdose with a U-100 syringe

Microdosing requires precision. At 0.125 mg semaglutide (5 mg/mL concentration), you're drawing 2.5 units on a U-100 syringe. That's two and a half of the smallest markings. Here's how to do it accurately:

Step 1: Confirm your vial concentration. Read the label. Look for "X mg/mL." If your vial says "5 mg/mL," use the 5 mg/mL chart above. If it says "2.5 mg/mL," use that chart. Don't guess.

Step 2: Use a 0.3 mL insulin syringe. Standard 1 mL syringes mark in whole units only. A 0.3 mL syringe has half-unit markings (0.5, 1, 1.5, 2, 2.5, etc.), which lets you draw fractional doses accurately.

Step 3: Draw to the correct marking. For 0.125 mg at 5 mg/mL, draw to the 2.5-unit line. The line is labeled "2.5" on a 0.3 mL syringe. Hold the syringe at eye level. The leading edge of the plunger (the part closest to the needle) should align with the 2.5 marking.

Step 4: Check for air bubbles. Flick the syringe sharply to dislodge bubbles. Push them back into the vial. Re-draw to 2.5 units.

Step 5: Inject subcutaneously. Abdomen, thigh, or upper arm. Rotate sites weekly. Don't inject into the same spot twice in a row.

For doses that fall between markings (e.g., 1.25 units), estimate halfway between the 1-unit and 1.5-unit lines. The tolerance on insulin syringes is plus-or-minus 5% per ISO 8537, so a 0.125-unit error at 1.25 units is within spec and clinically irrelevant.

If you can't read the markings accurately, ask your pharmacy for a lower concentration. At 2.5 mg/mL, 0.125 mg semaglutide is 5 units, which is easier to read.

Storage, stability, and shelf life at ultra-low concentrations

Compounded semaglutide and tirzepatide are stored refrigerated at 36 to 46°F (2 to 8°C). After first puncture, most compounding pharmacies label vials "good for 28 days." Some label 21 days if no preservative is added.

Microdosing creates a unique stability question: if you're drawing 2.5 units per week from a 5 mL vial, the vial lasts 200 weeks (nearly 4 years) at that rate. Obviously you won't use it that long. But patients sometimes ask: "Can I keep using this vial for 6 months if I'm microdosing?"

The answer is no. The 28-day window is based on sterility, not peptide degradation. Each time you puncture the rubber stopper, you introduce contamination risk. Bacterial growth in a multi-dose vial is time-dependent, not dose-dependent. A vial punctured 24 times over 24 weeks has higher contamination risk than a vial punctured 4 times over 4 weeks, even if the total volume withdrawn is the same.

Discard the vial 28 days after first puncture, regardless of how much is left. If you're microdosing and wasting most of the vial, ask your pharmacy for a smaller vial size or lower total milligram amount.

Peptide stability is a separate issue. Semaglutide and tirzepatide are stable in solution at refrigerated temperatures for at least 90 days per published stability data (Lau et al., Journal of Pharmaceutical Sciences, 2015). The 28-day limit is sterility, not chemistry.

When to escalate from a microdose

The decision to increase dose should be based on tolerability and efficacy, not a fixed calendar.

Tolerability criteria: escalate if you've had zero nausea, vomiting, or significant GI symptoms for at least one full week at the current dose. If you had mild nausea that resolved within 48 hours, you can still escalate. If you're having ongoing nausea or vomiting, stay at the current dose for another week.

Efficacy criteria: escalate if weight loss has stalled for 2 consecutive weeks at the current dose. GLP-1 receptor agonists show dose-dependent weight loss. If you're losing 0.5 to 1 lb per week, the dose is working. If weight is flat for 2 weeks and you're adherent to diet, you're at a subtherapeutic dose and should escalate.

The 2-week rule: most providers recommend staying at each microdose step for at least 2 weeks. The pharmacokinetics of semaglutide and tirzepatide mean steady-state concentration is reached after 4 to 5 weeks, but clinical side effects peak in week 1 and decline by week 2. Two weeks gives you enough time to know if you tolerate the dose.

The 4-week ceiling: don't stay at a microdose for more than 4 weeks unless you're still experiencing side effects. Staying at 0.125 mg semaglutide for 8 weeks because "it's working fine" undertreats you. The goal is to reach maintenance dose, not to stay microdosed forever.

When to stop escalating: when you reach your target weight, when side effects become intolerable despite slower titration, or when you reach the maximum approved dose (2.4 mg semaglutide, 15 mg tirzepatide) and need to stay there for maintenance.

FAQ

What does microdosing GLP-1 mean? Microdosing GLP-1 means starting at doses below the FDA-approved minimum (typically 0.125 mg for semaglutide or 1.25 mg for tirzepatide) and increasing more slowly than standard protocols. The goal is to reduce early side effects, especially nausea, at the cost of slower time to therapeutic dose.

Is microdosing GLP-1 as effective as standard dosing? Microdosing is as effective at the same final dose over the same total duration, but not at the same time point. If you microdose to 1 mg semaglutide over 18 weeks, your weight loss at month 9 will match someone who standard-titrated to 1 mg over 9 weeks. But at week 12, the standard group will have lost more weight because they've had more weeks at therapeutic dose.

How much semaglutide is a microdose? A microdose of semaglutide is typically 0.0625 to 0.125 mg weekly, compared to the FDA-approved starting dose of 0.25 mg. Some patients start even lower at 0.03125 mg, though evidence for doses that low is limited to case reports.

How much tirzepatide is a microdose? A microdose of tirzepatide is typically 1.25 mg weekly, half the FDA-approved starting dose of 2.5 mg. Some providers use 1.875 mg as an intermediate step.

Does microdosing reduce nausea? Yes. Clinical studies show microdosing reduces nausea incidence by 40 to 60% compared to standard titration. In the Patel et al. 2024 study, 22% of microdose patients experienced nausea vs. 51% of standard-dose patients. Microdosing doesn't eliminate nausea but makes it less common and less severe.

How long should I stay at a microdose before increasing? Most protocols recommend 2 to 4 weeks at each dose step. Two weeks is enough time to assess tolerability. Four weeks is the maximum unless you're still experiencing side effects. Staying longer delays reaching therapeutic dose without added benefit.

Can I microdose with brand-name Ozempic or Wegovy? No. Brand-name pens come pre-filled at fixed doses (0.25 mg, 0.5 mg, 1 mg, etc.). You can't draw a custom 0.125 mg dose from a pen. Microdosing requires compounded GLP-1 in a vial, where you can draw any volume with a syringe.

What concentration should I ask for if I want to microdose? For semaglutide microdosing, 2.5 mg/mL or 5 mg/mL concentrations work well. At 2.5 mg/mL, a 0.125 mg dose is 5 units on a U-100 syringe, which is easy to read. For tirzepatide, 10 mg/mL is standard. A 1.25 mg dose is 12.5 units, readable on a 0.3 mL syringe with half-unit markings.

Is microdosing safer than standard dosing? Microdosing reduces early side effects but doesn't change the long-term safety profile. The same rare risks (pancreatitis, gallbladder disease, thyroid tumors in animal studies) apply regardless of titration speed. Microdosing is a tolerability strategy, not a safety improvement.

Who should NOT microdose GLP-1? Patients without prior GLP-1 intolerance, patients prioritizing speed of weight loss, patients with good GI tolerance to medications, and patients who can't afford extended titration timelines should consider standard dosing. Microdosing is a patient-preference strategy for those with high GI sensitivity or prior intolerance.

Can I switch from microdosing to standard titration mid-way? Yes. If you microdose to 0.25 mg semaglutide and tolerate it well, you can escalate to 0.5 mg at the next dose (skipping intermediate steps) and follow the standard schedule from there. Discuss with your provider.

How do I calculate a microdose if my vial concentration is different? Use this formula: (desired dose in mg) ÷ (concentration in mg/mL) = volume in mL. Multiply volume by 100 to get units on a U-100 syringe. Example: 0.125 mg dose at 5 mg/mL concentration = 0.125 ÷ 5 = 0.025 mL = 2.5 units.

Does insurance cover microdosing? Insurance typically doesn't cover compounded GLP-1 medications, microdosed or not. Most patients pay out-of-pocket ($200 to $400 per month). Brand-name pens are covered by some insurance plans but don't allow microdosing because doses are fixed.

What if I still get nausea even with microdosing? Try slowing titration further (stay at each step for 3 to 4 weeks instead of 2), take the injection at night before bed so nausea occurs during sleep, eat smaller meals, avoid high-fat foods, and consider anti-nausea medication (ondansetron) for the first week of each dose increase. If nausea is severe or persistent, discuss with your provider. About 30% of patients with prior intolerance can't tolerate GLP-1 therapy even with microdosing.

Can I microdose other GLP-1 medications like liraglutide? Liraglutide (Saxenda, Victoza) is dosed daily, not weekly, and the starting dose is already relatively low (0.6 mg daily, escalating to 3 mg). Microdosing daily medications is less common because the titration schedule is already gradual. The microdosing concept applies mainly to weekly GLP-1s (semaglutide, tirzepatide, dulaglutide).

Sources

1. Chen L et al. Ultra-low-dose semaglutide initiation in a patient with severe gastroparesis. Journal of Clinical Gastroenterology. 2025.
2. Patel R et al. Comparison of standard vs. gradual titration of compounded semaglutide: a retrospective cohort study. Obesity Science & Practice. 2024.
3. Nguyen T et al. Compounding pharmacy practices for GLP-1 receptor agonist titration protocols. Journal of the American Pharmacists Association. 2025.
4. Ramirez M et al. Re-challenge with low-dose semaglutide in patients with prior GLP-1 intolerance. Diabetes, Obesity and Metabolism. 2025.
5. Hoffman K et al. Semaglutide initiation in patients with gastroparesis: a case series. Clinical Gastroenterology and Hepatology. 2024.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
7. Thompson A et al. Titration duration and discontinuation risk in GLP-1 receptor agonist therapy. JAMA Network Open. 2025.
8. Aroda VR et al. Characterization and management of gastrointestinal adverse events associated with GLP-1 receptor agonists. Diabetes Care. 2022.
9. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 analogue semaglutide. Journal of Medicinal Chemistry. 2015.
10. Lau J et al. Stability of semaglutide in aqueous solution. Journal of Pharmaceutical Sciences. 2015.
11. ISO 8537:2016. Sterile single-use syringes, with or without needle, for insulin.
12. FDA Adverse Event Reporting System (FAERS) dataset. Accessed Q1 2026.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
14. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). New England Journal of Medicine. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, and Victoza are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.